Acinetobacter cavitations in COVID-19 interstitial pneumonia: a case report and review of the literature

Submitted: 3 March 2023
Accepted: 10 March 2023
Published: 6 April 2023
Abstract Views: 230
PDF: 91
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Acinetobacter baumannii is commonly known to cause infection in immunocompromised patients. During COVID-19 pandemic, outbreaks of multidrug-resistant organisms, including Acinetobacter, have been well documented in acute care hospitals, particularly among critically ill patients. In the case reported, a woman was admitted to our ICU because of a severe COVID-19 pneumonia. During her stay, she worsened due to Acinetobacterrelated lung cavitations and only after proper antibiotic treatment she eventually recovered. To our knowledge, very few cases have been reported pointing to Acinetobacter as a causal agent for the acute development of lung cavities, especially in COVID-19 patients.



PlumX Metrics


Download data is not yet available.


Wong D, Nielsen TB, Bonomo RA, et al. Clinical and pathophysiological overview of Acinetobacter infections: A century of challenges. Clin Microbiol Rev 2017;30:409–47. DOI:
Boral J, Genç Z, Pınarlık F, et al. The association between Acinetobacter baumannii infections and the COVID-19 pandemic in an intensive care unit. Sci Rep 2022;12:1–7. DOI:
Eckardt P, Canavan K, Guran R, et al. Containment of a carbapenem-resistant Acinetobacter baumannii complex outbreak in a COVID-19 intensive care unit. Am J Infect Control 2022;50:477–81. DOI:
Perez S, Innes GK, Walters MS, et al. Increase in Hospital-Acquired Carbapenem-Resistant Acinetobacter baumannii Infection and Colonization in an Acute Care Hospital During a Surge in COVID-19 Admissions — New Jersey, February–July 2020. Morbidity and Mortality Weekly Report/Centers for Disease Control and Prevention. 2020;69. DOI:
Thoma R, Seneghini M, Seiffert SN, et al. The challenge of preventing and containing outbreaks of multidrug-resistant organisms and Candida auris during the coronavirus disease 2019 pandemic: report of a carbapenem-resistant Acinetobacter baumannii outbreak and a systematic review of the literatu. Antimicrob Resist Infect Control 2022;11:12. DOI:
Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: Emergence of a successful pathogen. Clin Microbiol Rev 2008;21:538–82. DOI:
Carvalheira A, Silva J, Teixeira P. Acinetobacter spp. in food and drinking water – A review. Food Microbiol 2021;95. DOI:
Nasr P. Genetics, epidemiology, and clinical manifestations of multidrug-resistant Acinetobacter baumannii. J Hosp Infect 2020;104:4–11. DOI:
Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006;42:692–9. DOI:
Lin M-F. Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases 2014;2:787. DOI:
Lee CR, Lee JH, Park M, et al. Biology of Acinetobacter baumannii: Pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol 2017;7:55. DOI:
Antunes LCS, Visca P, Towner KJ. Acinetobacter baumannii: Evolution of a global pathogen. Pathog Dis 2014;71:292–301. DOI:
Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J Infect Dis 2008;197:1079–81. DOI:
Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1–12. DOI:
Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007;5:939–51. DOI:
Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, et al. Acinetobacter baumannii ventilator-associated pneumonia: Epidemiological and clinical findings. Intensive Care Med 2005;31:649–55. DOI:
Nowak J, Zander E, Stefanik D, et al. High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. J Antimicrob Chemother 2017;72:3277–82. DOI:
Karakonstantis S, Kritsotakis EI, Gikas A. Pandrug-resistant gram-negative bacteria: A systematic review of current epidemiology, prognosis and treatment options. J Antimicrob Chemother 2020;75:271–82. DOI:
Inchai J, Pothirat C, Bumroongkit C, et al. Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care 2015;3:9. DOI:
Bassetti M, Taramasso L, Giacobbe DR, Pelosi P. Management of ventilator-associated pneumonia: Epidemiology, diagnosis and antimicrobial therapy. Expert Rev Anti Infect Ther 2012;10:585–96. DOI:
Hunt JP, Buechter KJ, Fakhry SM. Acinetobacter calcoaceticus pneumonia and the formation of pneumatoceles. J Trauma - Inj Infect Crit Care 2000;48:964–70. DOI:
Markelić I, Jakopović M, Klepetko W, et al. Lung abscess: an early complication of lung transplantation in a patient with cystic fibrosis. Int J organ Transplant Med 2017;8:213–6.
Cheng YF, Hsieh YK, Wang BY, et al. Tricuspid valve infective endocarditis complicated with multiple lung abscesses and thoracic empyema as different pathogens: A case report. J Cardiothorac Surg 2019;14:41. DOI:
Widysanto A, Liem M, Puspita KD, Pradhana CML. Management of necrotizing pneumonia with bronchopleural fistula caused by multidrug-resistant Acinetobacter baumannii. Respirol Case Reports 2020;8:e00662. DOI:
Wade P, Ananthan A, David J, Ghildiyal R. A case of acinetobacter septic pulmonary embolism in an infant. Case Rep Infect Dis 2016;2016:5241571. DOI:
Kokkonouzis I, Christou I, Athanasopoulos I, et al. Multiple lung abscesses due to acinetobacter infection: a case report. Cases J 2009;2:9347. DOI:
Yang CH, Chen KJ, Wang CK. Community-acquired Acinetobacter pneumonia: A case report. J Infect 1997;35:316–8. DOI:
Larcher R, Pantel A, Arnaud E, et al. First report of cavitary pneumonia due to community-acquired Acinetobacter pittii, study of virulence and overview of pathogenesis and treatment. BMC Infect Dis 2017;17:477. DOI:
Kaufman AE, Naidu S, Ramachandran S, et al. Review of radiographic findings in COVID-19. World J Radiol 2020;12:142–55. DOI:
Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): A systematic review of imaging findings in 919 patients. Am J Roentgenol 2020;215:87–93. DOI:
Xu Z, Pan A, Zhou H. Rare CT feature in a COVID-19 patient: cavitation. Diagnostic Interv Radiol 2020;26:380–1. DOI:
Afrazi A, Garcia-Rodriguez S, Maloney JD, Morgan CT. Cavitary lung lesions and pneumothorax in a healthy patient with active Coronavirus-19 (COVID-19) viral pneumonia. Interact Cardiovasc Thorac Surg 2021;32:150–2. DOI:
Zoumot Z, Bonilla MF, Wahla AS, et al. Pulmonary cavitation: an under-recognized late complication of severe COVID-19 lung disease. BMC Pulm Med 2021;21:24. DOI:
Muheim M, Weber FJ, Muggensturm P, Seiler E. An unusual course of disease in two patients with COVID-19: pulmonary cavitation. BMJ Case Rep 2020;13:e237967. DOI:
Zamani N, Aloosh O. Lung abscess as a complication of COVID-19 infection, a case report. Clin Case Reports 2021;9:1130–4. DOI:
Renaud-Picard B, Gallais F, Riou M, et al. Delayed pulmonary abscess following COVID-19 pneumonia: A case report. Respir Med Res 2020;78:100776. DOI:
Marchiori E, Nobre LF, Hochhegger B, Zanetti G. Pulmonary infarctions as the cause of bilateral cavitations in a patient with COVID-19. Diagnostic Interv Radiol 2020;27:690–1. DOI:
Selvaraj V, Dapaah-Afriyie K. Lung cavitation due to COVID-19 pneumonia. BMJ Case Rep 2020;13:e237245. DOI:
Ammar A, Drapé JL, Revel MP. Lung cavitation in COVID-19 pneumonia. Diagn Interv Imaging 2021;102:117–8. DOI:
Amaral LTW, Beraldo GL, Brito VM, et al. Lung cavitation in COVID-19: co-infection complication or rare evolution? Einstein (São Paulo) 2020;18:eAI5822. DOI:
Peeters K, Mesotten D, Willaert X, et al. Salvage lobectomy to treat necrotizing SARS-CoV-2 pneumonia complicated by a bronchopleural fistula. Ann Thorac Surg 2021;111:e241–3. DOI:
Yousaf Z, Khan AA, Chaudhary HA, et al. Cavitary pulmonary tuberculosis with COVID-19 coinfection. IDCases 2020;22:e00973. DOI:
Mishra A, George AA, Sahu KK, et al. Tuberculosis and COVID-19 co-infection: an updated review. Acta Biomed 2020;92:e2021025.
Rachina S, Kiyakbaev G, Antonova E, et al. A clinical case of nosocomial pneumonia as a complication of COVID-19: how to balance benefits and risks of immunosuppressive therapy? Antibiotics 2023;12. DOI:
Chowdhury T, Mainali A, Bellamkonda A, Gousy N. Acinetobacter: a rare cause of rapid development of cavitary lung lesion following COVID-19 infection. Cureus 2022;14. DOI:
Brahmbhatt N, Tamimi O, Ellison H, et al. Pneumatocele and cysts in a patient with severe acute respiratory syndrome coronavirus 2 infection. J Thorac Cardiovasc Surg Tech 2020;4:353–5. DOI:
Sanivarapu RR, Farraj K, Sayedy N, Anjum F. Rapidly developing large pneumatocele and spontaneous pneumothorax in SARS-CoV-2 infection. Respir Med Case Reports 2020;31:101303. DOI:
Capleton P, Ricketts W, Lau K, et al. Pneumothorax and pneumatocoele formation in a patient with COVID-19: a case report. SN Compr Clin Med 2021;1–4. DOI:
Hamad AM. Post COVID-19 large pneumatocele: clinical and pathological perspectives. Interact Cardiovasc Thorac Surg 2021;1–3. DOI:
Castiglioni M, Pelosi G, Meroni A, et al. Surgical resections of superinfected pneumatoceles in a COVID-19 patient. Ann Thorac Surg 2021;111:e23-5. DOI:

How to Cite

Di Bari, S., Raumer, L., Circelli, A., Viola, L., Gardelli, G., Bisulli, M., Cristini, F., & Russo, E. (2023). Acinetobacter cavitations in COVID-19 interstitial pneumonia: a case report and review of the literature. Acute Care Medicine Surgery and Anesthesia, 1(1).